Spanish Red Biotech Pipeline

Amgen

bemarituzumab

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Multicentric, open-label, phase 1b/2 basket trial, evaluating the safety and efficacy of bemarituzumab monotherapy in solid tumors with overexpression of FGFR2b (FORTITUDE-301)
Phase: 1Phase I in Spain